SCHEMBL24535899

SCHEMBL24535899

CC(C)(C)OC(=O)Nc1nn2c(c1I)CN(C(=O)OC(C)(C)C)CCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ NR1H2 P55055 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ GLS O94925 2/20 0.33
▸ CYBB P04839 1/20 0.33
▸ NOX5 Q96PH1 1/20 0.33
▸ NOX4 Q9NPH5 1/20 0.33
▸ NOX1 Q9Y5S8 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ ABL1 P00519 1/20 0.33
▸ RIN1 Q13671 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ PTPN2 P17706 1/20 0.33
▸ PTPN1 P18031 1/20 0.33
▸ PTPN6 P29350 1/20 0.33
▸ EPHX1 P07099 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29080101 0.91 OPRM1 (0.31) MAPT
SCHEMBL24535900 0.87 MEN1 (0.39) MAPTMEN1KMT2ANR1H2HPGD
SCHEMBL30793888 0.86 MAPT (0.37) MAPTMEN1KMT2ANR1H2HPGD
SCHEMBL25334805 0.86 MEN1 (0.40) MAPTMEN1KMT2ANR1H2HPGD
SCHEMBL30793812 0.84 F13A1 (0.36) MAPTMEN1KMT2ANR1H2HPGD
SCHEMBL25335700 0.81 NR1H2 (0.42) MAPTMEN1KMT2ANR1H2HPGD
SCHEMBL24535159 0.77 MEN1 (0.36) MAPTMEN1KMT2ANR1H2HPGD
SCHEMBL30793521 0.76 MEN1 (0.35) MAPTMEN1KMT2ANR1H2HPGD
SCHEMBL30793765 0.76 ADORA1 (0.42) MAPTMEN1KMT2ANR1H2HPGD
SCHEMBL24535901 0.74 MEN1 (0.43) MAPTMEN1KMT2ANR1H2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-04 — — US disclosed
EP-4540254-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023244604-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 — — WO disclosed
EP-4262807-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-10-25 — — EP disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 — — WO disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS MAPT 3384/4885MEN1 948/4885KMT2A 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback